Citadel Advisors
NBRV

Citadel Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Citadel Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,607
Closed -$20.1K – 15786
2023
Q1 		$20.1K Buy
+11,607
New +$19.5K ﹤0.01% 13068
2022
Q3 		– Sell
-7,152
Closed -$33K – 14309
2022
Q2 		$33K Buy
7,152
+6,649
+1,322% +$43.4K ﹤0.01% 12176
2022
Q1 		$5K Sell
503
-352
-41% -$4.28K ﹤0.01% 13434
2021
Q4 		$13K Sell
855
-2,020
-70% -$47.8K ﹤0.01% 13653
2021
Q3 		$86K Buy
2,875
+1,426
+98% +$40.3K ﹤0.01% 13014
2021
Q2 		$49K Sell
1,449
-2,681
-65% -$99.9K ﹤0.01% 13350
2021
Q1 		$171K Buy
4,130
+3,373
+446% +$210K ﹤0.01% 11909
2020
Q4 		$46K Buy
757
+638
+536% +$69.1K ﹤0.01% 10595
2020
Q3 		$16K Sell
119
-899
-88% -$150K ﹤0.01% 9903
2020
Q2 		$172K Buy
1,018
+514
+102% +$85.7K ﹤0.01% 8643
2020
Q1 		$72K Buy
+504
New +$154K ﹤0.01% 8844
2019
Q4 		– Sell
-85
Closed -$42K – 10076
2019
Q3 		$42K Sell
85
-32
-27% -$18K ﹤0.01% 8754
2019
Q2 		$71K Buy
117
+44
+60% +$27K ﹤0.01% 8635
2019
Q1 		$45K Buy
73
+12
+20% +$6.54K ﹤0.01% 8867
2018
Q4 		$22K Sell
61
-96
-61% -$51.6K ﹤0.01% 8720
2018
Q3 		$106K Buy
157
+3
+2% +$2.13K ﹤0.01% 8551
2018
Q2 		$134K Buy
154
+110
+250% +$126K ﹤0.01% 8118
2018
Q1 		$56K Buy
+44
New +$65.1K ﹤0.01% 7901

Other funds holding NBRV

VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AA
Addison Advisors Middlebury, Vermont $452M AUM 14.62% 1-Year Est. Return

Citadel Advisors's NBRV Position: Q2 2023 in Review

Citadel Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2023, closing a stake of 11,607 shares — an estimated $20.1K sold.

Citadel Advisors first reported a position in NBRV in Q1 2018 and held it in 18 quarters. The position peaked at $172K in Q2 2020. 9 funds tracked by Wall St. Rank hold NBRV as of Q2 2023.

  • Citadel Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 11,607 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2023, an estimated $20.1K.
  • Citadel Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2018 and held it in 18 quarters.
  • Citadel Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $172K in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.